Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Rosch Mark De is EVP, RA and GA and PgM at Cervomed. OQRO lists 2 transactions filed with the SEC under this name, the latest on Oct 23, 2026, each linked to the official Form 4.
EVP, RA and GA and PgM
Disclosures on record
2
Companies involved
1
CervomedCRVO
2 disclosures · Feb 2026 – Oct 2026
Oct 22, 202619Kdisclosed Oct 23
DetailsOfficial recordFeb 11, 202630Kdisclosed Feb 13
DetailsOfficial recordRosch Mark De has no open-market purchase on record since 2022. Sales in 1 of the 5 years since 2022.
Rosch Mark De reported 0 open-market purchases and 1 sale since 2022; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2022 | — | $14K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Rosch Mark De has no open-market purchase on record since 2022. Sales in 1 of the 5 years since 2022.
In SEC filings since 2022: no open-market purchase is on record; the latest open-market sale is from 2022.
Aura Biosciences (AURA), from 2022 to 2022: 0 purchases and 1 sale.
Rosch Mark De reported 0 open-market purchases and 1 sale here, 2022.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.